Field Trial FailureThe failure of the field trial, attributed to variability related to temperature, humidity, and pollen, accompanied the positive second resubmission chamber trial.
Investor SkepticismInvestors are skeptical of the approval of reproxalap in dry eye disease based solely on a positive resubmission chamber trial, as the stock is down.
Regulatory ChallengesIt's difficult not to be a little skeptical given the saga with this development program and the continuous issues that the FDA keeps bringing up even when management thinks everything is OK.